Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04347239 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19
A Phase 2 study, sponsored by CytoDyn.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
NCT04347239 is a Phase 2 study that has completed, run by CytoDyn. The registered enrollment target is 484 participants.
The verdict
NCT04347239, a Phase 2 study, has completed, sponsored by CytoDyn.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
Study Summary
The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
Interventions
- DRUG Placebo
- DRUG Leronlimab (700mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2020-04-16 |
| Est. Completion | 2022-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04347239
The ClinicalTrials.gov registry entry for NCT04347239 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 484 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoDyn, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04347239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04347239 about?
NCT04347239 is a clinical study titled "Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19". The purpose of this study was assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injection in subjects with severe or critical COVID-19 disease.
What is the current status of trial NCT04347239?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2020-04-16. Estimated completion is 2022-06-15.
What interventions are being tested in trial NCT04347239?
The interventions under investigation include: Placebo (DRUG), Leronlimab (700mg) (DRUG).
Who is sponsoring clinical trial NCT04347239?
This trial is sponsored by CytoDyn, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.